← All trials
NCT04516551
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2020
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 1, 2022
- First posted
- Aug 18, 2020
- Last posted
- Nov 17, 2020
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Anhui Medical UniversityCollaborator
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- People's Liberation Army of ChinaReponsible party - principal investigator
- People's Liberation Army of ChinaStudy chair
- People's Liberation Army of ChinaCollaborator
- People's Liberation Army of ChinaCollaborator
- Chongqing Medical UniversityCollaborator
- Gracell Biotechnology Ltd.Collaborator
- People's Liberation Army of ChinaCollaborator
- People's Liberation Army of ChinaCollaborator
- Gracell Biotechnology Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.